Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01365962|
Recruitment Status : Completed
First Posted : June 3, 2011
Last Update Posted : May 19, 2016
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies biomarkers in tumor tissue samples from patients with rhabdomyosarcoma.
|Condition or disease||Intervention/treatment|
|Sarcoma||Genetic: gene expression analysis Other: immunohistochemistry staining method Other: laboratory biomarker analysis Other: mass spectrometry|
- To determine and quantify the degree of surface insulin-like growth factor I receptor (IGF-IR) expression in rhabdomyosarcoma (RMS) tumor tissue.
- To assess the feasibility and validity of a mass spectrometry assay for IGF-IR expression on paraffin-embedded tumor tissue.
OUTLINE: Paraffin-embedded tumor tissue slides are analyzed for insulin-like growth factor I receptor (IGF-1R) expression by mass spectrometry and correlated with the results obtained by IHC assay.
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||A Study to Assess and Quantify Surface Insulin-like Growth Factor I Receptor (IGF-IR) in Rhabdomyosarcoma (RMS) Tumor Tissue|
|Study Start Date :||June 2011|
|Actual Primary Completion Date :||May 2016|
- Degree of surface IGF-IR expression in RMS tumor tissue
- Feasibility and validity of a mass spectrometry assay for IGF-IR expression on paraffin-embedded tumor tissue
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01365962
|Principal Investigator:||Suman Malempati, MD||Doernbecher Children's Hospital at Oregon Health and Science University|